What dose of corticosteroids (e.g. prednisolone) should be given to a 30-year-old male patient with dengue fever and suspected dengue maculopathy presenting with blurred vision?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Corticosteroid Dosing for Dengue Maculopathy

For a 30-year-old male with dengue fever and suspected dengue maculopathy presenting with blurred vision, initiate oral prednisolone at 0.5 to 1 mg/kg/day, tapered over 4 to 6 weeks. 1

Initial Assessment and Diagnosis

Before initiating corticosteroids, confirm dengue maculopathy through:

  • Fundoscopic examination looking for dilated veins, hyperemic optic discs, flame and blot hemorrhages, soft exudates, and macular ischemia 2
  • Optical coherence tomography (OCT) to identify vitreous cells, disruption of outer retinal layers (foveolitis), conical foveal elevation, or cystoid macular edema 1, 3
  • Positive dengue serology (NS1 antigen or dengue antibodies) 2, 1

Corticosteroid Treatment Protocol

Oral Corticosteroid Therapy (First-Line)

  • Dosing: Oral prednisolone 0.5 to 1 mg/kg/day 1
  • Duration: Taper over 4 to 6 weeks 1
  • Rationale: This dosing range has demonstrated resolution of vitreous cells, improvement in retinal layer integrity, and significant visual acuity improvement from mean 0.80 logMAR to 0.23 logMAR 1

The pathophysiology involves both inflammatory and ischemic components, with early corticosteroid therapy addressing the inflammation-driven vitreoretinal alterations 1. High-dose steroids have shown marked improvement in visual acuity and color vision in dengue maculopathy cases 2.

Alternative: Intravitreal Corticosteroid Therapy

For patients where systemic steroids are contraindicated or in elderly patients with bilateral severe disease:

  • Intravitreal triamcinolone acetonide injection in affected eyes 4
  • Timing: Can be performed at 3-day intervals between eyes if bilateral 4
  • Outcome: Rapid resolution of foveal lesions and macular edema with restoration of normal foveal architecture within 6 weeks 4

Monitoring Requirements

During corticosteroid therapy, monitor for:

  • Visual acuity improvement at regular intervals 1
  • OCT imaging to assess resolution of vitreous cells and restoration of outer retinal layer integrity 1
  • OCT angiography to evaluate persistent retinal plexus flow deficits, which correlate with initial visual acuity and may indicate permanent structural changes 1
  • Standard corticosteroid complications including hyperglycemia, hypertension, and gastrointestinal effects 1

Critical Considerations

Indications for systemic corticosteroids in dengue maculopathy include: 5

  • Poor presenting visual acuity
  • Progressive ocular symptoms
  • Lesions involving the optic nerve and/or threatening the macula

Expected outcomes:

  • Most cases show spontaneous improvement over 8 weeks to 4 months 2, 3
  • However, deep retinal plexus ischemia may persist despite corticosteroid therapy and cause permanent structural and functional changes 1
  • Complete recovery is possible, particularly in younger patients with early treatment 2, 3

Common pitfall: Delaying treatment in patients with bilateral involvement or optic nerve involvement, as these cases benefit most from early corticosteroid intervention 5. While many cases are self-limiting 3, patients with significant visual impairment (worse than 20/40) or bilateral disease warrant aggressive treatment 2, 1.

References

Research

Dengue maculopathy: a case report.

Travel medicine and infectious disease, 2007

Research

Dengue Stings the Eye!

Journal of clinical and diagnostic research : JCDR, 2017

Research

Ocular manifestations of dengue.

Current opinion in ophthalmology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.